Open Biosystems

Thermo Fisher Scientific this week announced that it will acquire Life Technologies for $13.6 billion in a deal that will bring together two of the largest providers of RNAi research products into a single entity.

While few details about the plaintiff in the case, PSN Illinois, were available, court filings indicate that the company has initiated numerous and varied patent-infringement suits in recent years.

According to Whitehead, Alnylam and Max Planck's request to block the case represents an "eleventh hour … rush into court to seek emergency relief from a situation of their own making," and should therefore be denied.

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.